The health‐economic impact of urine albumin‐to‐creatinine ratio testing for chronic kidney disease in Japanese patients with type 2 diabetes
ABSTRACT Aims/Introduction This analysis seeks to evaluate the cost‐effectiveness of urine albumin‐to‐creatinine ratio testing compared with urine protein‐creatinine ratio testing and no urine testing for the identification of kidney damage in individuals with type 2 diabetes who have, or are at ris...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Journal of Diabetes Investigation |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/jdi.14293 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850283722614505472 |
|---|---|
| author | Koichi Asahi Tsuneo Konta Kouichi Tamura Fumitaka Tanaka Akira Fukui Yusuke Nakamura Junichi Hirose Kenichi Ohara Yoko Shijoh Matthew Carter Kimberley Meredith James Harris Örjan Åkerborg Naoki Kashihara Takashi Yokoo |
| author_facet | Koichi Asahi Tsuneo Konta Kouichi Tamura Fumitaka Tanaka Akira Fukui Yusuke Nakamura Junichi Hirose Kenichi Ohara Yoko Shijoh Matthew Carter Kimberley Meredith James Harris Örjan Åkerborg Naoki Kashihara Takashi Yokoo |
| author_sort | Koichi Asahi |
| collection | DOAJ |
| description | ABSTRACT Aims/Introduction This analysis seeks to evaluate the cost‐effectiveness of urine albumin‐to‐creatinine ratio testing compared with urine protein‐creatinine ratio testing and no urine testing for the identification of kidney damage in individuals with type 2 diabetes who have, or are at risk of, chronic kidney disease in Japan. Materials and Methods A health‐economic model estimated the clinical and economic consequences of different tests to evaluate kidney damage in line with Japanese guidelines, taking a Japanese healthcare perspective. Differences in the diagnostic performance of tests were considered by the integration of real‐world Japanese data. Outcomes were considered over a lifetime horizon, and included costs, prevented dialyses, life years gained, quality‐adjusted life years, and incremental cost‐effectiveness ratios. Results Repeated urine albumin‐to‐creatinine ratio testing was found to be cost‐effective compared with both urine protein‐creatinine ratio testing and no urine testing, yielding incremental cost‐effectiveness ratios of ¥2,652,693 and ¥2,460,453, respectively. Conclusions Repeated urine albumin‐to‐creatinine ratio testing is cost‐effective compared with urine protein‐creatinine ratio testing and no urine testing in Japanese individuals with type 2 diabetes, supporting existing clinical evidence that albumin‐to‐creatinine ratio testing should be used more widely, particularly compared with other urine tests such as urine protein‐creatinine ratio testing. |
| format | Article |
| id | doaj-art-1364e07d45ad4b57be9fc72145d4e4fd |
| institution | OA Journals |
| issn | 2040-1116 2040-1124 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Investigation |
| spelling | doaj-art-1364e07d45ad4b57be9fc72145d4e4fd2025-08-20T01:47:43ZengWileyJournal of Diabetes Investigation2040-11162040-11242025-01-0116110811910.1111/jdi.14293The health‐economic impact of urine albumin‐to‐creatinine ratio testing for chronic kidney disease in Japanese patients with type 2 diabetesKoichi Asahi0Tsuneo Konta1Kouichi Tamura2Fumitaka Tanaka3Akira Fukui4Yusuke Nakamura5Junichi Hirose6Kenichi Ohara7Yoko Shijoh8Matthew Carter9Kimberley Meredith10James Harris11Örjan Åkerborg12Naoki Kashihara13Takashi Yokoo14Division of Nephrology and Hypertension, Department of Internal Medicine Iwate Medical University School of Medicine Morioka Iwate JapanDepartment of Public Health and Hygiene Yamagata University Graduate School of Medicine Yamagata Yamagata JapanDepartment of Medical Science and Cardiorenal Medicine Yokohama City University Graduate School of Medicine Yokohama Kanagawa JapanDivision of Nephrology and Hypertension, Department of Internal Medicine Iwate Medical University School of Medicine Morioka Iwate JapanDivision of Nephrology and Hypertension, Department of Internal Medicine The Jikei University School of Medicine Minato Tokyo JapanBayer Yakuhin Ltd Osaka Osaka JapanBayer Yakuhin Ltd Osaka Osaka JapanBayer Yakuhin Ltd Osaka Osaka JapanBayer Yakuhin Ltd Osaka Osaka JapanWickenstones Ltd Carlow IrelandWickenstones Ltd Carlow IrelandWickenstones Ltd Carlow IrelandWickenstones Ltd Carlow IrelandKawasaki Geriatric Medical Center Okayama Okayama JapanDivision of Nephrology and Hypertension, Department of Internal Medicine The Jikei University School of Medicine Minato Tokyo JapanABSTRACT Aims/Introduction This analysis seeks to evaluate the cost‐effectiveness of urine albumin‐to‐creatinine ratio testing compared with urine protein‐creatinine ratio testing and no urine testing for the identification of kidney damage in individuals with type 2 diabetes who have, or are at risk of, chronic kidney disease in Japan. Materials and Methods A health‐economic model estimated the clinical and economic consequences of different tests to evaluate kidney damage in line with Japanese guidelines, taking a Japanese healthcare perspective. Differences in the diagnostic performance of tests were considered by the integration of real‐world Japanese data. Outcomes were considered over a lifetime horizon, and included costs, prevented dialyses, life years gained, quality‐adjusted life years, and incremental cost‐effectiveness ratios. Results Repeated urine albumin‐to‐creatinine ratio testing was found to be cost‐effective compared with both urine protein‐creatinine ratio testing and no urine testing, yielding incremental cost‐effectiveness ratios of ¥2,652,693 and ¥2,460,453, respectively. Conclusions Repeated urine albumin‐to‐creatinine ratio testing is cost‐effective compared with urine protein‐creatinine ratio testing and no urine testing in Japanese individuals with type 2 diabetes, supporting existing clinical evidence that albumin‐to‐creatinine ratio testing should be used more widely, particularly compared with other urine tests such as urine protein‐creatinine ratio testing.https://doi.org/10.1111/jdi.14293AlbuminuriaCost‐effectiveness analysisDiabetes mellitus |
| spellingShingle | Koichi Asahi Tsuneo Konta Kouichi Tamura Fumitaka Tanaka Akira Fukui Yusuke Nakamura Junichi Hirose Kenichi Ohara Yoko Shijoh Matthew Carter Kimberley Meredith James Harris Örjan Åkerborg Naoki Kashihara Takashi Yokoo The health‐economic impact of urine albumin‐to‐creatinine ratio testing for chronic kidney disease in Japanese patients with type 2 diabetes Journal of Diabetes Investigation Albuminuria Cost‐effectiveness analysis Diabetes mellitus |
| title | The health‐economic impact of urine albumin‐to‐creatinine ratio testing for chronic kidney disease in Japanese patients with type 2 diabetes |
| title_full | The health‐economic impact of urine albumin‐to‐creatinine ratio testing for chronic kidney disease in Japanese patients with type 2 diabetes |
| title_fullStr | The health‐economic impact of urine albumin‐to‐creatinine ratio testing for chronic kidney disease in Japanese patients with type 2 diabetes |
| title_full_unstemmed | The health‐economic impact of urine albumin‐to‐creatinine ratio testing for chronic kidney disease in Japanese patients with type 2 diabetes |
| title_short | The health‐economic impact of urine albumin‐to‐creatinine ratio testing for chronic kidney disease in Japanese patients with type 2 diabetes |
| title_sort | health economic impact of urine albumin to creatinine ratio testing for chronic kidney disease in japanese patients with type 2 diabetes |
| topic | Albuminuria Cost‐effectiveness analysis Diabetes mellitus |
| url | https://doi.org/10.1111/jdi.14293 |
| work_keys_str_mv | AT koichiasahi thehealtheconomicimpactofurinealbumintocreatinineratiotestingforchronickidneydiseaseinjapanesepatientswithtype2diabetes AT tsuneokonta thehealtheconomicimpactofurinealbumintocreatinineratiotestingforchronickidneydiseaseinjapanesepatientswithtype2diabetes AT kouichitamura thehealtheconomicimpactofurinealbumintocreatinineratiotestingforchronickidneydiseaseinjapanesepatientswithtype2diabetes AT fumitakatanaka thehealtheconomicimpactofurinealbumintocreatinineratiotestingforchronickidneydiseaseinjapanesepatientswithtype2diabetes AT akirafukui thehealtheconomicimpactofurinealbumintocreatinineratiotestingforchronickidneydiseaseinjapanesepatientswithtype2diabetes AT yusukenakamura thehealtheconomicimpactofurinealbumintocreatinineratiotestingforchronickidneydiseaseinjapanesepatientswithtype2diabetes AT junichihirose thehealtheconomicimpactofurinealbumintocreatinineratiotestingforchronickidneydiseaseinjapanesepatientswithtype2diabetes AT kenichiohara thehealtheconomicimpactofurinealbumintocreatinineratiotestingforchronickidneydiseaseinjapanesepatientswithtype2diabetes AT yokoshijoh thehealtheconomicimpactofurinealbumintocreatinineratiotestingforchronickidneydiseaseinjapanesepatientswithtype2diabetes AT matthewcarter thehealtheconomicimpactofurinealbumintocreatinineratiotestingforchronickidneydiseaseinjapanesepatientswithtype2diabetes AT kimberleymeredith thehealtheconomicimpactofurinealbumintocreatinineratiotestingforchronickidneydiseaseinjapanesepatientswithtype2diabetes AT jamesharris thehealtheconomicimpactofurinealbumintocreatinineratiotestingforchronickidneydiseaseinjapanesepatientswithtype2diabetes AT orjanakerborg thehealtheconomicimpactofurinealbumintocreatinineratiotestingforchronickidneydiseaseinjapanesepatientswithtype2diabetes AT naokikashihara thehealtheconomicimpactofurinealbumintocreatinineratiotestingforchronickidneydiseaseinjapanesepatientswithtype2diabetes AT takashiyokoo thehealtheconomicimpactofurinealbumintocreatinineratiotestingforchronickidneydiseaseinjapanesepatientswithtype2diabetes AT koichiasahi healtheconomicimpactofurinealbumintocreatinineratiotestingforchronickidneydiseaseinjapanesepatientswithtype2diabetes AT tsuneokonta healtheconomicimpactofurinealbumintocreatinineratiotestingforchronickidneydiseaseinjapanesepatientswithtype2diabetes AT kouichitamura healtheconomicimpactofurinealbumintocreatinineratiotestingforchronickidneydiseaseinjapanesepatientswithtype2diabetes AT fumitakatanaka healtheconomicimpactofurinealbumintocreatinineratiotestingforchronickidneydiseaseinjapanesepatientswithtype2diabetes AT akirafukui healtheconomicimpactofurinealbumintocreatinineratiotestingforchronickidneydiseaseinjapanesepatientswithtype2diabetes AT yusukenakamura healtheconomicimpactofurinealbumintocreatinineratiotestingforchronickidneydiseaseinjapanesepatientswithtype2diabetes AT junichihirose healtheconomicimpactofurinealbumintocreatinineratiotestingforchronickidneydiseaseinjapanesepatientswithtype2diabetes AT kenichiohara healtheconomicimpactofurinealbumintocreatinineratiotestingforchronickidneydiseaseinjapanesepatientswithtype2diabetes AT yokoshijoh healtheconomicimpactofurinealbumintocreatinineratiotestingforchronickidneydiseaseinjapanesepatientswithtype2diabetes AT matthewcarter healtheconomicimpactofurinealbumintocreatinineratiotestingforchronickidneydiseaseinjapanesepatientswithtype2diabetes AT kimberleymeredith healtheconomicimpactofurinealbumintocreatinineratiotestingforchronickidneydiseaseinjapanesepatientswithtype2diabetes AT jamesharris healtheconomicimpactofurinealbumintocreatinineratiotestingforchronickidneydiseaseinjapanesepatientswithtype2diabetes AT orjanakerborg healtheconomicimpactofurinealbumintocreatinineratiotestingforchronickidneydiseaseinjapanesepatientswithtype2diabetes AT naokikashihara healtheconomicimpactofurinealbumintocreatinineratiotestingforchronickidneydiseaseinjapanesepatientswithtype2diabetes AT takashiyokoo healtheconomicimpactofurinealbumintocreatinineratiotestingforchronickidneydiseaseinjapanesepatientswithtype2diabetes |